Building CNS health and wellness using scientific approaches.
Our Projects
The speed, fidelity, and predictability of the NeuroTheryX Technology Platform has allowed the company to establish an exciting pipeline of Development Projects:
Lead Project
Small molecule oral formulation drugs for the therapeutic intervention of Primary Progressive Multiple Sclerosis:
A “new chemical entity” (NCE) class – defined by a series of granted patents – first drug candidate is a game-changing oral formulation therapeutic designed to repair myelin and treat progressive Multiple Sclerosis (MS). Project to be developed towards Phase I clinical trials in humans.
Artificial Intelligence and phenotype-based design of synthetic “new chemical entity” cannabinoids:
We are developing the next generation of novel cannabinoid-inspired therapeutics for mental health and neuropsychiatric disorders. Formed through a partnership between Cyclica and NeuroTheryX, this project was empowered to uncover more effective medicines for complex neurological disorders. By bridging AI-augmented technologies with an established phenotype-based platform - we have designed the next level generation of pharmaceutical cannabinoids.